Building the Future of Cancer Care. Together.

CascaDTx is developing LumiTx, a next-generation oncology digital therapeutic platform. We are in an exciting early phase and are seeking partners and investors to accelerate development and scale impact.

Why Invest in CascaDTx?

CascaDTx is addressing a massive unmet need in cancer care by tackling side effects, adherence, and emotional stress that current tools ignore. Purpose-built for oncology, CascaDTx applies the proven model of regulated digital therapeutics to reduce adverse events, lower costs, and generate real-world data for payors and pharma. Led by seasoned pharma and biotech founders with a personal commitment to improving cancer care, CascaDTx is positioned to transform patient outcomes and create significant value.

  • High unmet need – Cancer patients face side effects, adherence challenges, and emotional stress not addressed by existing tools.

  • Oncology focus – LumiTx is built specifically for oncology, with future applications in chemo- and radiotherapy.

  • Proven model – Digital therapeutics (DTx) are recognized globally as a regulated, evidence-based category.

  • Value creation – Reduce adverse events, lower healthcare costs, and generate real-world data for payors and pharma partners.

  • Experienced founders – Decades of pharma/biotech expertise plus a deeply personal commitment to improving cancer care.

Our Momentum

We are at the transition from concept to platform:

  • MVP design defined and under development.

  • Regulatory and SaMD-aligned roadmap established.

  • IP strategy focused on trusted data, AI-elevation, and clinical insights.

  • Early stakeholder conversations underway (patients, clinicians, pharma).

Now is the ideal time to join us at the ground floor — helping shape a platform built on DTx standards and designed for oncology impact.

Co-Development Opportunities

We are seeking strategic partners to co-create value through:

  • Clinical trials & validation (oncology centres, universities, academic hospitals).

  • Pharma collaborations (drug + DTx combinations, real-world data generation).

  • Health system pilots (value-based care, AE reduction).

  • Technology partnerships (AI, data platforms, digital biomarkers).

Join Us

We’re building the future of oncology care on the global DTx pillars of safety, privacy, and clinical evidence. Every step of development is transparent, ethical, and driven by data, with a patient-first, therapy-first design to deliver maximum impact. Together, we can transform cancer care into something safer, smarter, and more human.

Be part of shaping the future of oncology care.

  • Investors – Help accelerate development and scale impact.

  • Clinicians & pharma partners – Co-develop digital therapeutics that transform outcomes.

  • Health systems & payors – Explore pilots that improve care quality and reduce costs.